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Abstract
The cost-effectiveness of the ProbeTec ET Direct TB assay
(DTB) was compared with that of culture for detection of Myco-
bacterium tuberculosis complex in 361 acid-fast stain-positive
respiratory specimens. The overall sensitivity, specificity, positive
predictive value and negative predictive value of DTB were
97.7%, 86.6%, 87.2% and 97.6%, respectively. When clinical eval-
uation was added to DTB, the specificity and positive predictive
value of DTB increased to 94.7% and 95.4%, respectively. Treat-
ment costs of $133 521 would have been saved in this cohort if
DTB, instead of culture results, had been used to eliminate
‘false-positive’ smear results.
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Initial screening for active pulmonary tuberculosis (TB) is
usually performed by staining for acid-fast bacilli (AFB), but
this fast and inexpensive test cannot distinguish Mycobacte-
rium tuberculosis complex (MTB) from non-tuberculosis
mycobacteria (NTM) [1,2]. To protect the public from the
possible spread of this very contagious disease, patients with
‘false-positive’ stains are treated with antibiotics until sputum
culture demonstrates the absence of MTB, a period of
3–6 weeks. A reliable and rapid method for eliminating
‘false-positive’ AFB smear results would decrease the finan-
cial burden on the healthcare system and the adverse effects
on patients of receiving unnecessary antibiotic treatment
while awaiting sputum culture results.
The ProbeTec ET direct TB assay (DTB; Mycobacterium
tuberculosis complex TB Direct Detection Assay; Becton
Dickinson, Sparks, MD, USA) for the detection of MTB is
highly specific and time-saving [3–6]. It is sensitive when used
to verify AFB-positive smear results, and can thus be used
for early detection of TB cases [7]. The objective of this
study was to assess the reliability DTB in detecting TB
cases among AFB-positive specimens, and to determine the
potential cost saving in patient care resulting from the use of
this assay.
Three hundred and sixty-one AFB-positive respiratory
secretion specimens from 325 patients with symptoms of
pneumonia or pulmonary TB were collected at Kaohsiung
Veterans General Hospital and used for DTB and culture. If
the patients had more than one set of AFB-positive samples
within 3 months, we selected only one set to detect TB with
the DTB. All patients provided informed consent. Clinical
procedures were approved by our institutional review board.
Smears were stained with Kinyoun acid-fast stain. AFB
counts were defined as follows: ‘not found,’ 0/300 field;
‘doubtful,’ 1–2/300 field; AFB 1+, 1–9/100 field; AFB 2+, 1–9/
10 field; AFB 3+, 1–9/field; AFB 4+, >9/field [8,9]. Culture at
35C for 6 and 8 weeks was performed as previously
described [9,10].
DTB on AFB-positive specimens was performed weekly,
according to the manufacturer’s instructions [11].
Clinical evaluation included granulomatous inflammation
with or without caseous necrosis in a lung or lymph node
biopsy specimen, predominant upper lobe infiltrates, cavita-
tion or miliary patterns in chest radiographs, AFB detected
in histopathological studies of excisional biopsy specimens,
and favourable anti-TB treatment.
Calculation of the total cost, including the costs of anti-
biotics, isolation ward, medicines service, doctor consulta-
tions (including chest X-ray, sputum smears and cultures)
and other related expenses, was performed for the positive
AFB stain cohort [12].
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Specimens were analysed by using a count and percentage
for categorical variables. Kappa analysis was used to assess
interobserver agreement between DTB and culture results.
It was found that 54.3% (196/361) of DTB results and
48.5% (175/361) of culture results for AFB-positive smears
were positive (Table 1). A small fraction of DTB results
were inconclusive, because of the presence of inhibitory sub-
stances (3.3%, 12/361), but, unlike acid-fast staining, DTB
clearly distinguished between tuberculous mycobacteria and
NTM.
When compared with culture results alone, DTB showed
a sensitivity of 97.7%, a specificity of 86.6%, a positive predic-
tive value of 87.2% and a negative predictive value of 97.6%.
However, 16 patients with negative culture results (seven
with no bacterial growth, four with contamination, and five
with NTM) were diagnosed with TB by clinical evaluation. If
we defined positive TB cases according to both clinical
evaluation and culture results, the sensitivity and specificity
of the DTB assay increased to 97.9% and 94.7%, the positive
and negative predictive values were 95.4% and 97.6%, and
the kappa value was 0.93.
In Taiwan, current guidelines are that symptomatic
patients should immediately receive anti-TB therapy for
14 days in an isolation ward if one or more specimens are
AFB-positive. Forty-four per cent (71/161) of the ‘false-
positive’ smear patients were treated as outpatients, and
56% (90/161) as inpatients; the latter were transferred to
the isolation ward for 14 days of therapy. All were treated
with antituberculosis drugs (average of 35.6 days/patient)
until culture results were available (Table 2). The total cost
was US$1771.5 for a hospitalized patient found to be
TB-negative by culture, but only $330.3 for a patient found
to be TB-negative by DTB. The total cost for an outpatient
was $85.3 if false positives were eliminated through culture
and $31.3 if they were eliminated by DTB. Hence, substitut-
ing DTB for culture saved $1441.2 per hospitalized patient
and $54 per outpatient case. In the cohort described here,
in which 56% were treated as hospitalized patients and 44%
as outpatients, a total saving of US$133 521 saving would
have been made if DTB had been used to eliminate all ‘false
positives’ (Table 2).
The major advantage of DTB over culture for the identifi-
cation of positive smears for TB is that DTB takes 4 h
instead of the 3–6 weeks necessary for culture.
DTB is a rapid technique for identification of the M. tuber-
culosis complex directly from AFB-positive clinical specimens.
Its negative predictive power in this study is 97.6%, a result
that is similar to that of others [7], and its sensitivity is over
95%. Although DTB costs more than culture, it can reduce
TABLE 1. Comparison of results between DTB and culture
results in smear-positive samples
DTB
MTB culture results
Positive Negative
a
Positive 171 (187)b 25 (9)b
Negative 4 161
MTB, Mycobacterium tuberculosis complex.
aMTB culture negative, including no growth, growth of non-tuberculosis myco-
bacteria (NTM) or contaminated by bacteria
bCulture results adjusted to include 16 culture-negative patients with a clinical
diagnosis of MTB (seven culture specimens had no growth, four specimens
were contaminated by bacteria, and five specimens grew NTM), then left nine
specimen true negative.
TABLE 2. Analysis of cost savings resulting from the use of DTB for confirmation of 161 non-tuberculosis patients
Observed
Conventional medication DTB
Ward, 14 days (90 cases)
Outpatient
(71 cases)
Ward, 3 days (90
cases)
Outpatient
(71 cases)Daily Total Daily Total
Hospital costs
Hospitalization 71.4 999.6 – 51.3 153.8 –
Antibioticsa 1.5 21 – 1.5 4.5 –
Sputum culture 14.1 14.1 – – – –
Other medical 46.9 656.6 – 46.9 140.7 –
DTB – – – 31.3 31.3 31.3
Total (US$) 180.8 1691.3 0 131 330.3 31.3
Outpatient costs
Outpatient 17.8 17.8 17.8 – – –
Continue antibioticsa 1.5 32.4 (21.6 days) 53.4 (35.6 days) – – –
Sputum culture 14.1 – – –
Total (US$) 19.3 50.2 85.3 0 0 0
Per person 200.1 1771.5 85.3 131 330.3 31.3
Cost (161 patients) 165 470 31 949
Saving (US$) 133 521
aThe cost of antimicrobial therapy for tuberculosis for 14 days in the isolation ward per patient was US$21. The average number of days before culture-negative results were
confirmed was 35.6, so outpatient antibiotic therapy was continued for 21.6 days, at a cost of US$180.8.
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costs by reducing unnecessary hospitalization and medication
for patients with ‘false-positive’ initial AFB smears.
Acknowledgements
This study was supported in part by the National Health
Research Institute (NHRI-CL-095-PP-07) and Kaohsiung
Veterans General Hospital (VGHKS 097-067).
Transparency Declaration
All authors declare no potential conflicts of interest.
References
1. Boyd JC, Marr JJ. Decreasing reliability of acid-fast smear techniques
for detection of tuberculosis. Ann Intern Med 1975; 82: 489–492.
2. Murray PR, Elmore C, Krogstad DJ. The acid-fast stain: a specific and
predictive test for mycobacterial disease. Ann Intern Med 1980; 92:
512–513.
3. Barrett A, Magee JG, Freeman R. An evaluation of the BD ProbeTec
ET system for the direct detection of Mycobacterium tuberculosis in
respiratory samples. J Med Microbiol 2002; 51: 895–898.
4. Huang TS, Huang WK, Lee SS, Tu HZ, Chang SH, Liu YC. Rapid
detection of pulmonary tuberculosis using the SDA Mycobacterium
tuberculosis complex Direct Detection Assay (DTB). Diagn Microbiol
Infect Dis 2003; 46: 29–33.
5. Mazzarelli G, Rindi L, Piccoli P, Scarparo C, Garzelli C, Tortoli E.
Evaluation of the BDProbeTec ET system for direct detection of
Mycobacterium tuberculosis in pulmonary and extrapulmonary samples:
a multicenter study. J Clin Microbiol 2003; 41: 1779–1782.
6. Dinnes J, Deeks J, Kunst H et al. A systematic review of rapid diag-
nostic tests for the detection of tuberculosis infection. Health Technol
Assess 2007; 11: 1–196.
7. Piersimoni C, Scarparo C. Relevance of commercial amplification
methods for direct detection of Mycobacterium tuberculosis complex in
clinical samples. J Clin Microbiol 2003; 41: 5355–5365.
8. Koneman EW, Allen SD, Dowell VR, Sommers HM. Mycobacteria. In:
Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC
Jr, eds. Color atlas and textbook of diagnostic microbiology, 4th edn.
Philadelphia, PA: Lippincott, 1992; 703–755.
9. Nolte FS, Metchock B. Mycobacterium. In: Murray PR, Baron EJ,
Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical micro-
biology, 6th edn. Washington, DC: American Society for Microbiology,
1995; 400–437.
10. Tu HZ, Chang SH, Huaug TS, Huaug WK, Liu YC, Lee SS. Micro-
scopic morphology in smears prepared from MGIT broth medium
for rapid presumptive identification of Mycobacterium tuberculosis
complex, Mycobacterium avium complex and Mycobacterium kansasii.
Ann Clin Lab Sci 2003; 33: 179–183.
11. Walker GT, Nadeau JG, Spears PA, Schram JL, Nycz CM, Shank DD.
Multiplex strand displacement amplification (SDA) and detection of
DNA sequences from Mycobacterium tuberculosis and other mycobac-
teria. Nucleic Acids Res 1994; 22: 2670–2677.
12. Centers for Disease Control, Taiwan. Tuberculosis medical expenses in
the CDC budget in Taiwan area. Taipei, Taiwan: Centers for Disease
Control, 2003.
Resistance class 1 integron in clinical
methicillin-resistant Staphylococcus aureus
strains in southern China, 2001–2006
Z. Xu1,2, L. Li1, M. E. Shirtliff2,3, B. M. Peters2,4, B. Li1,
Y. Peng5, M. J. Alam6, S. Yamasaki1,7 and L. Shi1,7
1) College of Light Industry and Food Sciences, South China University of
Technology, Guangzhou, China, 2) Department of Microbial Pathogenesis,
Dental School, University of Maryland, Baltimore, MD, 3) Department of
Microbiology and Immunology, School of Medicine, University of Maryland,
Baltimore, MD, 4) Graduate Program in Life Sciences, Molecular Microbi-
ology and Immunology Program, University of Maryland, Baltimore, MD,
USA, 5) The Biological Safety Level 3 Laboratory, Sun Yat-sen University,
Guangzhou, China, 6) College of Agriculture & Life Sciences, Texas A &
M University, College Station, TX, USA and 7) Graduate School of Life
and Environmental Sciences, Osaka Prefecture University, Osaka, Japan
Abstract
As a novel antibiotic resistance determinant, investigation of the
occurrence and characteristics of class 1 integron was performed
on nosocomial methicillin-resistant Staphylococcus aureus (MRSA)
strains sampled during 2001–2006. Seventy-six out of 179 (42.5%)
of the tested strains were found to carry class 1 integrons, with
four unique arrays of gene cassettes detected. This is the first
report of the comprehensive identification and typing of class 1 in-
tegrons in clinical MRSA isolates over a 6-year period, represent-
ing the first evidence for class 1 integrons as possible antibiotic
resistance determinants in clinical MRSA strains.
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